Trastuzumab Plus Pertuzumab Versus Cetuximab Plus Irinotecan in Patients With

• Tác giả: Nitya Alluri, E Gabriela Chiorean, Sarah Colby, Larry R Corum, N Arvind Dasari, Crystal S Denlinger, Benjamin T Esparaz, Marwan Fakih, Sepideh Gholami, Philip J Gold, Katherine A Guthrie, Lee G Hicks, Howard S Hochster, Syed M Kazmi, Scott Kopetz, Michael J Overman, Mital S Patel, Philip A Philip, Kanwal Pratap Singh Raghav, Benjamin Tan
• Ngôn ngữ: eng
• Ký hiệu phân loại: 373.236 Lower level
• Thông tin xuất bản: United States : Journal of clinical oncology : official journal of the American Society of Clinical Oncology , 2025
• Bộ sưu tập: NCBI
• ID: 700817

Tóm tắt

METHODS: Patients with RESULTS: Between October 2017 and March 2022, 54 participants were assigned to TP (n = 26) and CETIRI (n = 28). Median PFS did not vary significantly by treatment: 4.7 (95% CI, 1.9 to 7.6) and 3.7 (95% CI, 1.6 to 6.7) months in the TP and CETIRI groups, respectively. Efficacy of TP versus CETIRI differed significantly by CONCLUSION: TP appears to be a safe and effective cytotoxic chemotherapy-free option for patients with